Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
First signals of gabapentinoid abuse occurred in the last decade. This study aims to describe clinical characteristics of gabapentinoid use related disorders and health consequences in France. The route of administration was primarily oral for pregabalin and gabapentin, with opioids demonstrating a smaller relative prevalence of oral administration as assessed by GTNet. Conclusions: The rates of abuse of pregabalin and gabapentin were low and much less than with opioids in France, Germany and Italy. When pregabalin or gabapentin were First signals of gabapentinoid abuse occurred in the last decade. This study aims to describe clinical characteristics of gabapentinoid use related disorders and health consequences in France. Gabapentin was first approved in France in 1994 for the treatment of partial seizures, and secondarily extended to post‐zoster and neuropathic pain in 2000. Background: Gabapentinoids (i.e., gabapentin and pregabalin) are medications approved for epilepsy, chronic pain, or generalized anxiety disorder. Recently, there have been regular reports of misuse of pregabalin, and to a lesser extent, gabapentin, in particular among opioid and polydrug users. Gabapentin is a prescription medication that was approved by the U.S. Food and Drug Administration in 1993 as a treatment for epilepsy. It works by binding to a type of calcium channel in nerve Parke-Davis' Neurontin in France 15 October 1995 - Parke-Davis' Neurontin (gabapentin) is now available on prescription in France as an add-on therapy for the treatment of partial seizures in epileptic patients who do not respond to first-line therapy alone. • The rates of abuse of pregabalin and gabapentin were low in relation to other drugs, including opioids, across France, Germany, and Italy. – Cumulative rate of lifetime abuse was highest in Germany (for all drugs). • When pregabalin or gabapentin were abused, they were generally abused along with another drug, and rarely In this large population‐based study of all first‐time pregabalin, gabapentin and duloxetine users in France, we found that misuse was more frequent among pregabalin users (12.8% were dispensed a dose that exceeded the maximum recommended dose), compared to gabapentin (6.6%) and duloxetine users (9.7%). Our study reveals a local but substantial increase in gabapentinoid use in populations with no social insurance. These findings should be confirmed more widely and plead for the systematic collection of anonymous patient data in free healthcare centers in France. Introduction: Gabapentinoid drugs (gabapentin and pregabalin) are widely used worldwide for epileptic and pain disorders. First signals of gabapentinoid abuse occurred in the last decade. This study aims to describe clinical characteristics of gabapentinoid use related disorders and health consequences in France. Materials and Methods: We designed a multisource investigation reviewing data En France, l’évolution de la consommation de gabapentinoïdes est suivie par l’ANSM à travers les programmes du réseau français d’addictovigilance, ainsi que le dispositif TREND de l’OFDT (observatoire français des drogues et des toxicomanies). Aims: The aim of this study was to assess the use and factors associated with the misuse of gabapentin and pregabalin in the general French population, through a cohort study in the EGB (General Sample of Beneficiaries), a national representative sample of the French general population. (SUD) is higher (pregabalin: 3–68%; gabapentin: 15–22%) (1). In a systematic review aimed to evaluate the abuse liability of gabapentin and pregabalin, the authors found that pregabalin had a greater potential for addiction than gabapentin based on the magnitude of behavioral dependence symptoms, transitions In France, only a few cases of gabapentin misuse and abuse have been reported until 2014 (13–15). In 2011, a first case of recreational use of pregabalin has been reported by a general Gabapentin (International) In the US, Gabapentin (gabapentin systemic) is a member of the drug class gamma-aminobutyric acid analogs and is used to treat Alcohol Use Disorder, Alcohol Withdrawal, Anxiety, Back Pain, Benign Essential Tremor, Bipolar Disorder, Burning Mouth Syndrome, Carpal Tunnel Syndrome, Chronic Kidney Disease-Associated Pruritus, Chronic Pain, Cluster-Tic Syndrome, Cough The responsibility for updating information regarding the regulations for travellers carrying medicines containing controlled substances lies entirely with the Governments concerned. 2 Unité Mixte de Recherche, 1027 Inserm-Université, Pharmacoépidémiologie, Université de Toulouse, France. 3 Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP), Service de Pharmacologie Médicale et Clinique, CHU de Toulouse, France. 4 Centre d'Investigation Clinique, 1436 Inserm CHU, CHU de Toulouse Alors qu’en France l’abus et le mésusage de la prégabaline dépassent de loin ceux de la gabapentine, les pharmacologues du réseau français d’addictovigilance alertaient dès 2019 sur le risque de report vers la gabapentine. In France, only a few cases of gabapentin misuse and abuse have been reported until 2014 (13–15). In 2011, a first case of recreational use of pregabalin has been reported by a general practitioner in 2011 and received particular attention by the French Addictovigilance Network (FAN) as an early signal for pregabalin abuse potential.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |